Immunotherapy in Early-Stage Breast Cancer - Report from ESMO BC 2026

Professor Giampaolo Bianchini discusses the evolving landscape of immunotherapy in early-stage breast cancer, focusing on predictive biomarkers, patient selection, and the integration of checkpoint inhibitors into neoadjuvant and adjuvant treatment settings to improve long-term outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:immunotherapy-early-stage-breast-cancer-report-esmo-bc-2026